People · Operator
Named in public records as an officer, director or promoter · active 2008–2011 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $86.8M | $2.7B | 2011 |
| Taligen Therapeutics Inc | — | Biotechnology | Series B | $62.1M | $1.4B | 2008 |
John C. Maraganore at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John C. Maraganore on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Ed Hurwitz | 1 | 9 |
| Nicholas Galakatos | 1 | 6 |
| Doug Cole | 1 | 6 |
| ABBIE CELNIKER | 1 | 6 |
| Nicholas C. Galakatos | 1 | 3 |
| Timothy C Mills | 1 | 3 |
| DAVID SCHENKEIN | 1 | 2 |
| Perry C. Karsen | 1 | 1 |
| Kevin C. Starr | 1 | 1 |
| Lewis C. Cantley | 1 | 1 |
| Duncan Higgons | 1 | 1 |
| Marc C. Tessier-Lavigne | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.